Table 1 Key inclusion and exclusion criteria
From: Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Inclusion criteria | Exclusion criteria |
|---|---|
Visual acuity 20/32 (80 EDTRS letters at 4 m) to 20/320 (30 EDTRS letters 4 m chart) | visual acuity worse than 20/320 |
Macular oedema secondary to diabetic retinopathy. (OCT thickness of > 300 µm central subfield, on spectral domain OCT (Spectralis Heidelberg engineering) | Rubeosis |
Peripheral ischaemia seen on UWFFA (20% of the peripheral retina or more) | Proliferative diabetic retinopathy |
Patient able to give consent and take part in all study procedures | No recent change to antihypertensive treatment within 2 months of start of study |
BP >180/110 mmHg (if elevated, treatment may be modified, and patients may subsequently be considered for recruitment after at least 2 months on new treatment regime) | |
Unable to give consent or take part in all study procedures | |
Other conditions that might interfere with the assessment of the eye such as cataract or prevent the macular oedema from settling such as vitreomacular traction, epiretinal membrane, to a degree that would in the opinion of the investigator affect response to treatment; conditions that would prevent the visual acuity improving such as foveal atrophy, uveitis | |
Previous macular laser within 4 months in the study eye | |
Previous peripheral (PRP) laser in the study eye | |
Previous injection therapy within last 6 months in the study eye | |
Pregnant | |
Uncontrolled systemic illness that in the opinion of the investigator would preclude involvement | |
Systemic steroid treatment within 3 months of recruitment, or during the study | |
Cataract or other intraocular surgery within 3 months | |
Previous vitrectomy |
